Cancer cells often exhibit altered cellular metabolism and maintain an acidic environment that fosters their growth and survival. By targeting V-ATPases, concanamycin A can disrupt the pH balance within cancer cells, leading to their death. Additionally, V-ATPases are involved in the autophagy process, which cancer cells use to survive under stress conditions. Inhibiting V-ATPases can thus impair the autophagic process, making cancer cells more susceptible to other treatments.
